177 related articles for article (PubMed ID: 29353821)
1. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
2. Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: a subanalysis of a multicenter, open-label phase I/II study.
Takekoshi K; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Asada S; Kawata N; Naruse M
Endocr J; 2019 Dec; 66(12):1063-1072. PubMed ID: 31511435
[TBL] [Abstract][Full Text] [Related]
3. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Metyrosine Improves Cardiovascular Outcomes for Patients Undergoing Surgery for Pheochromocytoma and Paraganglioma.
Wachtel H; Kennedy EH; Zaheer S; Bartlett EK; Fishbein L; Roses RE; Fraker DL; Cohen DL
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S646-54. PubMed ID: 26374407
[TBL] [Abstract][Full Text] [Related]
5. Metyrosine and pheochromocytoma.
Steinsapir J; Carr AA; Prisant LM; Bransome ED
Arch Intern Med; 1997 Apr; 157(8):901-6. PubMed ID: 9129550
[TBL] [Abstract][Full Text] [Related]
6. The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.
Ohmachi Y; Yamamoto M; Inaba Y; Makino S; Urai S; Matsumoto R; Bando H; Kanie K; Tsujimoto Y; Motomura Y; Sasaki Y; Oi-Yo Y; Yamamoto N; Suzuki M; Takahashi M; Iguchi G; Kanzawa M; Furukawa J; Shigemura K; Mizobuchi S; Ogawa W; Fukuoka H
Endocrine; 2024 May; 84(2):694-703. PubMed ID: 38206436
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
[TBL] [Abstract][Full Text] [Related]
8. Surgical management of pheochromocytoma with the use of metyrosine.
Perry RR; Keiser HR; Norton JA; Wall RT; Robertson CN; Travis W; Pass HI; Walther MM; Linehan WM
Ann Surg; 1990 Nov; 212(5):621-8. PubMed ID: 1978640
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of High-Specific-Activity
Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
[TBL] [Abstract][Full Text] [Related]
10. Failure of metyrosine therapy for preoperative management of pheochromocytoma: a case report.
Thanapaalasingham K; Pollmann AS; Schelew B
Can J Anaesth; 2015 Dec; 62(12):1303-7. PubMed ID: 26362800
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
12. Preoperative treatment and survival of patients with pheochromocytomas.
Sand J; Salmi J; Saaristo J; Auvinen O
Ann Chir Gynaecol; 1997; 86(3):230-2. PubMed ID: 9435934
[TBL] [Abstract][Full Text] [Related]
13. Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma.
Matsuo Y; Ashida K; Nagayama A; Moritaka K; Gobaru M; Yasuda J; Ogasawara N; Kurose H; Chikui K; Iwata S; Inoguchi Y; Hasuzawa N; Motomura S; Igawa T; Nomura M
Endocr Oncol; 2023 Jan; 3(1):e230006. PubMed ID: 37822367
[TBL] [Abstract][Full Text] [Related]
14. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
Tanabe A; Naruse M; Nomura K; Tsuiki M; Tsumagari A; Ichihara A
Horm Cancer; 2013 Apr; 4(2):103-10. PubMed ID: 23361939
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
Christensen TT; Frystyk J; Poulsen PL
Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
Huang H; Abraham J; Hung E; Averbuch S; Merino M; Steinberg SM; Pacak K; Fojo T
Cancer; 2008 Oct; 113(8):2020-8. PubMed ID: 18780317
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors.
Procopiou M; Finney H; Akker SA; Chew SL; Drake WM; Burrin J; Grossman AB
Eur J Endocrinol; 2009 Jul; 161(1):131-40. PubMed ID: 19383804
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy.
Fujiwara Y; Ohmoto A; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Yuasa T; Yonese J; Takahashi S
Endocr J; 2021 Jun; 68(6):671-681. PubMed ID: 33518616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
